Nystagmus.
This article reviews some of the past year's important papers, with emphasis on early onset and acquired neurological nystagmus. Advances in understanding the mechanisms of suppression of oscillopsia, the evolution of nystagmus, and the treatment of periodic alternating nystagmus and of nystagmus in albinism have been made in early-onset nystagmus. Successful pharmacological treatment for acquired neurological nystagmus has been demonstrated with the gamma aminobutyric acid agonist gabapentin and with memantine, a glutamate antagonist.
Gottlob
I
I
Department of Strabismus and Neuro-Ophthalmology, Kantonsspital St. Gallen, Switzerland.
D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D018756:GABA Antagonists / Q000627:therapeutic use; D006801:Humans; D009422:Nervous System Diseases / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D009759:Nystagmus, Pathologic / Q000150:complications / Q000151:congenital / Q000188:drug therapy
D018691:Excitatory Amino Acid Antagonists; D018756:GABA Antagonists